Phillip Stoup

关于 Phillip Stoup

Phillip’s practice focuses on advising companies and underwriters on a range of capital markets transactions, including IPOs and other equity offerings, convertible and other debt offerings and strategic investments. He also advises companies on securities law compliance, general corporate and governance matters. He has extensive experience advising companies in the life sciences and technology sectors.

Phillip draws on experience with robust deal flow — he has advised on billions of dollars' worth of financings — and a global perspective gained from six years working in London.

近期项目经验

IPOs

• CARGO Therapeutics’ $281 million initial public offering 
• Neumora Therapeutics’ $250 million initial public offering
• Corsair Gaming’s $238 million initial public offering 
• Arteris’ $70 million initial public offering
• Paragon 28’s $125 million initial public offering
• Eliem Therapeutics’ $80 million initial public offering 
• Treace Medical Concepts’ $105 million initial public offering
• 4D Molecular Therapeutics’ $193 million initial public offering 
• Silverback Therapeutics’ $241 million initial public offering 
• Eargo’s $141 million initial public offering
• Kronos Bio’s $250 million initial public offering 
• Allogene’s $324 million initial public offering 
• Restoration Robotics’ $25 million initial public offering
• ObsEva SA’s $96 million initial public offering of common stock
• Protagonist Therapeutics’ $90 million initial public offering of common stock

Other Equity Transactions

• Allogene’s $110 million follow-on offering of common stock
• Neumora Therapeutics on the establishment of its “at-the-market” offering for up to $250 million
• Corvus Pharmaceuticals on the establishment of its “at-the-market” offering for up to $100 million
• Opendoor on the establishment of its “at-the-market” offering for up to $200 million
• Corvus Pharmaceuticals on the $30 million offering of its common stock, pre-funded warrants and common stock warrants
• Absci Corporation’s $75 million follow-on offering of common stock
• BridgeBio Pharma’s $250 million follow-on offering of common stock
• 4D Molecular Therapeutics' $300 million follow-on offering of common stock
• Alpine Immune Sciences’ $150 million follow-on offering of common stock
• Coherus' $50 million offering of its common stock
• 4D Molecular's $300 million follow-on offering of common stock
• BridgeBio Pharma’s $150 million follow-on offering of common stock
• Bloom Energy's $338 million offering of its common stock
• Alpine Immune Sciences’ $100 million follow-on offering of common stock
• Athenex’s $30 million follow-on offering of common stock, pre-funded warrants and warrants
• Chinook Therapeutics’ $105 million follow-on offering of common stock and pre-funded warrants
• Twist Bioscience’s $250 million follow-on offering of common stock
• Twist Bioscience’s $300 million follow-on offering of common stock
• Athenex’s $110 million follow-on offering of common stock
• Zealand Pharma’s $100 million follow-on offering of common stock
• Myokardia’s $550 million follow-on offering of common stock
• Allogene’s $550 million follow-on offering of common stock
• Athenex’s $65 million follow-on offering of common stock
• AveXis’ $400 million follow-on offering of common stock
• Protagonist Therapeutics’ $60 million follow-on offering of common stock
• Ascendis' $135 million follow-on offering of ADSs
• Coherus on Temasek’s private investment of $150 million in Coherus’ common stock
• AveXis’ $287 million follow-on offering of common stock
• Codexis' $25 million follow-on offering of common stock
• AveXis’ $168 million follow-on offering of common stock 
• Elger Biopharmaceuticals’ $20 million follow-on offering of common stock

Debt Transactions

• BridgeBio Pharma’s $650 million convertible senior notes offering
• Bloom Energy's $200 million green convertible senior notes offering
• Coherus' $200 million green convertible senior notes offering
• PDL BioPHarma’s $150 million senior convertible notes offering
• Coherus on the $76 million royalty and term loan financing transaction with Barings

deSPAC Transactions

• Obagi Skincare on its deSPAC and merger transaction
• Planet Labs on its deSPAC and merger transaction